Product Pipeline
Ondek is developing an exciting product portfolio using its platform technology, HPPT.
Ondek’s first product will be a human influenza vaccine, the development of which has been supported by AusIndustry.
The target market for Ondek’s influenza vaccine is the market created by common influenza and pandemic outbreaks of influenza.
Annual influenza epidemics are thought to infect 5-15% of the world population each year, cause 3 to 5 million cases of severe illness, and between 250,000 and 500,000 deaths, according to the World Health Organization.
The global influenza vaccine market estimated at US$1.6 billion in 2005, projected to reach US$3.7 billion by 2010. Ondek’s HPPT based vaccine will offer significant benefits over existing products including:
- oral administration;
- sustained delivery so that no boosters are required;
- no requirement for large refrigerated stockpiles;
- reduced administration costs (with few trained personnel or equipment required);
- low production costs; and
- the ability to be delivered directly to the mucosa of the gut where Helicobacter Pylori has already been shown to be highly immunogenic
HPPT also offers a significant point of differentiation in the market for chronic diseases such as obesity, hypertension and diabetes. The opportunity for Ondek in this market is to improve the efficacy of existing vaccines and drugs. Ondek will be expanding its product pipeline through the development of products for these markets in the near future.